“Trends and Challenges in Immuno-Oncology” was moderated by Jennifer Kim and Rosemary L.. It featured James Oliviero, CFA, President & CEO of Checkpoint Therapeutics Inc, Marc Voigt, CEO of Immutep Limited, Frank Bedu-Addo, CEO of PDS Biotechnology, and Ian Walters, CEO of Portage Biotech Inc.

• Checkpoint Therapeutics discussed the potential differentiation of cosibelimab (anti-PD-L1) from currently marketed anti-PD-1s and anti-PD-L1s, as well as the company’s planned disruptive pricing strategy to gain market share, and its interest in evaluating potential synergistic combinations.

• Immutep is dedicated to the development of LAG-3 therapeutics. The company highlighted eftilagimod alpha (“efti”), the company’s first-in-class LAG-3 antigen-presenting cell (APC) activator product candidate, and its potential differentiation from other LAG-3 competitors.

• PDS Biotechnology discussed how T cells are not all created equally – the right potency, phenotype, and quantity are needed – and highlighted the potential competitive advantages of its Versamune platform-based oncology pipeline, including recent data updates for lead asset, PDS0101.

• Portage spoke about the unique ability of iNKT cells to bridge the adaptive and innate immune systems. It also touched upon how its adenosine and iNKT assets can work together to combat the immunosuppressive tumor micro-environment.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare